Offering 'skimpy plans' and subsidies, Republicans ready for battle on Trumpcare again

14 July 2017

Republicans in the Senate, the primary legislative body in the USA, have at last revealed their latest, secretly-drafted, proposal to replace the Affordable Care Act.

The bill including elements put forward by hard liner and failed presidential candidate Ted Cruz, including so-called ‘skimpy plans’ - bare-bones insurance coverage that falls below the minimum standards set by Obamacare.

By tacking to the right, majority leader Mitch McConnell hopes to pick up enough votes from the conservative wing of the party to see the bill through its final legislative hurdle, a vote in the Senate.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK